Biospring Partners

Labviva, Inc. operates a digital marketplace tailored for the life sciences sector, connecting researchers with suppliers of reagents, chemicals, and laboratory equipment. Founded in 2015 and based in Somerville, Massachusetts, the platform offers a wide range of products, including antibodies, biological kits, buffers, chromatography supplies, and various laboratory devices. Labviva enhances the user experience by leveraging scientific context to streamline the procurement process, making it easier for suppliers to manage product content. Its Inventory Management System provides real-time inventory tracking and AI-driven purchase automation, thus improving operational efficiency and compliance. By offering insights into lab purchasing trends and supply chain health, Labviva enables clients to maintain contract pricing with preferred vendors and establish direct partnerships without the complexity of managing multiple catalogs.

Labviva, Inc. operates a digital marketplace tailored for the life sciences sector, connecting researchers with suppliers of reagents, chemicals, and laboratory equipment. Founded in 2015 and based in Somerville, Massachusetts, the platform offers a wide range of products, including antibodies, biological kits, buffers, chromatography supplies, and various laboratory devices. Labviva enhances the user experience by leveraging scientific context to streamline the procurement process, making it easier for suppliers to manage product content. Its Inventory Management System provides real-time inventory tracking and AI-driven purchase automation, thus improving operational efficiency and compliance. By offering insights into lab purchasing trends and supply chain health, Labviva enables clients to maintain contract pricing with preferred vendors and establish direct partnerships without the complexity of managing multiple catalogs.

Abzena plc is a biopharmaceutical services company that specializes in the development and manufacturing of biologics and antibody-drug conjugates (ADCs). Operating internationally, it provides a comprehensive range of technologies and solutions that support the discovery, development, and production of biopharmaceutical products. Abzena's offerings include advanced antibody engineering, immunogenicity assessment, and various bioassay and bioanalytic services. The company assists clients from initial concept through to clinical development, focusing on enhancing the efficacy and safety of biotherapeutics. Its services also encompass peptide synthesis, process development, and the characterization of drug conjugates. By partnering with biopharmaceutical companies and academic institutions, Abzena aims to drive innovation and improve therapeutic outcomes for patients. Founded in 2014 and headquartered in Cambridge, United Kingdom, Abzena has positioned itself as a key player in the biologics research sector.

KINICITI is a platform established by Welsh, Carson, Anderson & Stowe that focuses on partnering with companies poised to transform the cell and gene therapy ecosystem. The organization aims to address persistent challenges in the development, manufacturing, and delivery of innovative treatments, ensuring these therapies reach patients in a cost-effective manner. By providing resources, expertise, and capital, KINICITI supports life science companies in scaling their operations and delivering significant customer value. Its investment strategy is centered on opportunities that harness technology and capabilities to drive meaningful change, ultimately facilitating the advancement and adoption of cell and gene therapies for those in need.

ixlayer is a prominent player in the health-tech sector, specializing in virtual health testing solutions for health systems, payors, biopharma, and health-focused organizations. Founded in 2018, the company provides a comprehensive platform that addresses the technical, security, regulatory, and user experience aspects of complex health testing. As the healthcare landscape increasingly embraces remote care, ixlayer enhances patient engagement and supports preventative health strategies through scalable virtual testing options. The platform can be integrated into existing patient engagement systems and portals, facilitating real-time health and wellness lab testing. ixlayer currently serves millions of patients and has successfully launched numerous testing programs for major organizations, health systems, and government entities.

Abzena plc is a biopharmaceutical services company that specializes in the development and manufacturing of biologics and antibody-drug conjugates (ADCs). Operating internationally, it provides a comprehensive range of technologies and solutions that support the discovery, development, and production of biopharmaceutical products. Abzena's offerings include advanced antibody engineering, immunogenicity assessment, and various bioassay and bioanalytic services. The company assists clients from initial concept through to clinical development, focusing on enhancing the efficacy and safety of biotherapeutics. Its services also encompass peptide synthesis, process development, and the characterization of drug conjugates. By partnering with biopharmaceutical companies and academic institutions, Abzena aims to drive innovation and improve therapeutic outcomes for patients. Founded in 2014 and headquartered in Cambridge, United Kingdom, Abzena has positioned itself as a key player in the biologics research sector.